Endothelial Function and Cardiovascular Health
Mohsin Wali1, C. Venkata S. Ram2,3,4

1Department of Medicine, Sir Ganga Ram Hospital and Ganga Ram Institute of Post Graduate Medical Education and Research, New Delhi, India, 2Apollo Institute for Blood Pressure Management, World Hypertension League/South Asia Office, Apollo Hospitals, and Apollo Medical College, Hyderabad, Telangana, India, 3Texas Blood Pressure Institute, University of Texas Southwestern Medical School, Dallas, U.S.A, 4India Campus, Macquarie University, Medical School, Sydney, Australia

Abstract
Systemic vascular disease is a major public health issue all over the world. Vascular disease causes significant morbidity and excessive mortality. Risk factors for vascular disease like hypertension, diabetes, hyperlipidemia, and tobacco consumption inflict vascular disease by causing endothelial dysfunction. Endothelium, the innermost layer of the blood vessels governs vascular tone and vasomotion. Abnormal endothelial function promotes vasoconstriction and atherothrombosis. Thus, endothelial dysfunction predisposes to vascular disease affecting target organs — brain, heart, and the kidneys, etc. Endothelial dysfunction, thus, is a precursor in the onset and progression of systemic vascular disease and atherosclerosis. Future interventions to prevent vascular disease should include modalities to preserve endothelial function and to reverse endothelial dysfunction. Endothelial function is critical to maintain holistic public health.

Key words: Cardiovascular Disease (CVD), Endothelium, homeostasis

Cardiovascular disease (CVD) is the leading global cause of premature mortality and excessive morbidity. A number of predisposing factors contribute to the pathogenesis of CVD. Etiological factors such as hypertension, diabetes, obesity, sedentary life style, tobacco consumption, and genetics participate in the onset and progression of CVD. Age and gender may also play an important role in the causation of CVD. An important critical fundamental basis for CVD is endothelial dysfunction. Circulatory homeostasis is regulated by the cells that line the vascular system — the endothelium. Originally, endothelium was merely considered as an inactive physical barrier between the blood and vascular smooth muscle but it is now recognized as playing a central role in the development of vascular disease/atherosclerosis. While it is not absolutely clear whether it is the cause or consequence of CVD, endothelium is intimately linked to vascular pathology. Given its (physical) location between the blood stream and vascular smooth muscle, endothelium is the locus for biological and mechanical actions of cardiovascular risk factors.

The endothelium is the largest organ in the body serving paracrine, endocrine, and numerous other regulatory functions in determining the cardiovascular health and CVD [Figure 1]. In response mechanical, biological, and endocrine stimuli, endothelium produces vasoactive substances which govern the vascular structure and function. The consequences of this phenomenon are vasoconstriction or vasodilation or thrombus formation. Endothelium thus controls vascular remodeling, hemostasis, and inflammation. A principal function of the endothelium is to regulate vasomotor tone (contraction or dilation) [Table 1]. A prominent function of endothelium is nitric oxide (NO) metabolism and other vasodilatory substances such as prostacyclins. The endothelium [Figures 2 and 3] also modulates vasoconstrictor components such as thromboxane A2, endothelin, and angiotensin II [Figure 4]. The vascular growth factors are also modulated by the endothelium. In other words, the endothelium is the maestro conducting the cardiovascular orchestra [Figures 5 and 6].

Address for correspondence:
C. Venkata S. Ram, Apollo Institute for Blood Pressure Management, World Hypertension League/South Asia Office, Apollo Hospitals, and Apollo Medical College, Hyderabad, Telangana, India. E-mail: drram_v@apollohospitals.com

Received: 23/03/2021; Accepted: 31/03/2021
doi: 10.15713/ins.johtn.0214
The seminal discovery by Furchgott of endothelium derived relaxing factor (EDRF) confirmed that normal endothelium is essential to induce vasodilation. Subsequent research has led to uncovering that EDRF is NO. Endothelium produces NO by stimulating guanosine monophosphate (GMP). NO regulates vasomotor tone, myocardial contractility, cell permeability, vascular proliferation, and exerts anti-thrombotic effects. NO synthase produces NO from L-arginine. NO synthase in the endothelium is acNOS, an inducible enzyme. In the normally functioning endothelium, acNOS continually produces NO to maintain physiological vasodilation constantly.

In addition, bradykinin and acetylcholine also stimulate ecNOS. Hypoxemia and vascular sheer stress are important stimuli for the release of NO. It is of interest to note that NO production is highest in the small arteries (resistance vessels) but NO activity is highest in the large diameter arteries. NO is involved in acto-regulation of blood flow in the arteries of all sizes, thus assuring required distribution of blood among various vascular networks. NO also modulates growth factors and vasoconstrictors. During atherogenesis, platelet-derived growth factor (PDGF) –β inhibits the activity of NO. Thus, positive and negative control mechanisms are present in the endothelium.

**Prostacyclin and Bradykinin**

Prostacyclin is elaborated in response to shear stress and other factors influencing NO. But when compared to NO, the contribution of prostacyclin to vasodilation is negligible. Endothelial cells produce and release bradykinin in response to...
blood flow. Bradykinin in turn binds to β2 receptor to activate L-arginine – NO pathway. Bradykinin has dual vasodilating properties – direct and indirect through stimulation of NO. Bradykinin causes nitrite release from coronary arteries. Bradykinin (like NO) also inhibits platelet aggregation and thrombosis. By stimulating tissue plasminogen activator (t-PA), bradykinin promotes an anti-thrombotic effect.

**Vasocontracting factors/endothelium**

Endothelium may prevent vasodilation or cause vasoconstriction through thrombin, acetylcholine, arachidonic acid, prostaglandin, H2, and high potassium levels as well as by hypoxia and vascular stretch. Examples of endothelium derived contracting factors include endoperoxides and thromboxane A2.
Figure 4: ET-1: Generation, action, and pathophysiology

Figure 5: Known contributors of endothelia dysfunction

Figure 6: Vasodilation and vasoconstriction
**Endothelin**

Endothelin, a 21 - amino acid peptide is a potent vasoconstrictor. It is produced by the endothelin in response to thrombin, angiotensin II, arginine vasopressin, interleukin - I, and calcium ionophores, etc. In healthy individuals, circulating levels of endothelin are very low. Endothelin production is influenced by cGMP-dependent inhibition, cAMP-dependent inhibition, and an inhibitory factor produced by vascular smooth muscle cells. Formation of NO by normal endothelium offsets the negative actions of endothelin.

**Angiotensin II**

Angiotensin II is a powerful vasoconstrictor produced by angiotensin converting enzyme present in the endothelial cells. In addition to causing direct vasoconstriction, angiotensin II stimulates endothelin and hence with resultant vasoconstriction.

**Endothelium dependent – vasomotion**

The pivotal role of endothelium --- dependent vasodilation in maintaining normal vasomotion is a well-established concept. It is well known that acetylcholine, an endothelium --- dependent factor causes coronary vasorelaxation in the normal vessels but causes paradoxical vasoconstriction in atherosclerosis arteries. The paradoxical vasoconstriction is explained by the loss of normal endothelial function in the diseased arteries. This pathological observation is seen well before the angiographic dissection of atherosclerotic lesions. Substances that inactive NO such as methylene blue and free hemoglobin blocks acetylcholine mediated vasodilation. In addition to NO, other endothelium derived vasodilators such as histamine and substance P cause coronary vessel dilation.

In summary, vascular endothelium plays a major role in maintaining vascular tone and tissue blood flow in health and in disease.

**Vascular growth**

The endothelium produces a number of growth factors such as --- fibroblast growth factor, PDGF, angiotensin II, and endothelin. At the same time, the endothelial cells also produce growth inhibitors such as TGF-β, heparan sulfates, and heparin. Importantly, NO has significant anti-proliferative effects. NO inhibits vascular smooth muscle proliferation and fibroblast mitogenesis. Overexpression of NOs and precursors of NO inhibit and prevent endothelial injury. The superoxide generation by angiotensin II can be blocked by NO.

**Anti-coagulant effects**

The normal endothelium maintain a critical balance between the factors that regulate fibrinolysis and thrombosis. The endothelium protects against thrombus formation by synthesizing glycosaminoglycans that bind to antithrombin. The endothelial cells synthesize thrombomodulin which transforms thrombin and converts it to an activator of protein C; these activated proteins have anticoagulant properties. In addition, protein C – causes fibrinolysis (through interaction with plasminogen activator inhibitor [PAI]). A vital fibrinolytic property of the endothelium is its ability to produce t-PA that converts plasminogen to plasmin. Endothelial cells synthesize PAI-1 which determines the rate of fibrinolysis. The balance between t-PA and PAI-1 is tilted toward thrombosis by angiotensin II.

The endothelial cells can inhibit platelet aggregation and adhesion, prostacyclin produced by the endothelium also blocks platelet activation. Platelets also contain NO synthase which is turned on by platelet aggregation. NO blocks ADP-induced platelet adhesion and aggregation. In totality then, NO inhibits platelet adhesion to the vascular endothelial cells. The antithrombotic actions of endothelium are due to synergistic effects of NO and prostacyclin. The vasospasm and thrombus formation are prevented by joint actions of NO and prostacyclin.

**Anti-inflammatory effects**

Leukocyte adhesion is attenuated by NO produced by the endothelium. NO also inactivates superoxide anion. Deficiency of NO causes vascular permeability and protein leakage hallmarks of vascular inflammation. An imbalance between NO and superoxide anion induces vascular inflammation by promoting leukocyte migration and mast cells. The endothelial cells normally prevent leukocyte adhesion, damaged endothelium expresses leukocyte adhesion molecules which is a pro-inflammatory state. Oxidized LDL cholesterol also causes an inflammatory reaction in the endothelium. The metabolic stress induced by hypertension and hyperlipidemia, for example, causes superoxide anion generation and vascular smooth muscle hypertrophy.

**NO and anti-atherosclerotic effects**

Besides blocking the leukocyte-endothelial interaction, NO also prevents other mechanisms involved in atherosclerosis. NO inhibits vascular smooth muscle hypertrophy and migration and eliminates oxidative modification of LDL. NO deficiency results in vascular dysfunction and thrombus formation. Low levels of NO may stimulate angiotensin and block bradykinin production. NO blocks adhesion molecules and chemotactic proteins. For all these reasons, NO is considered as an natural anti-atherogenic molecule. Exposure to vascular shear stress augments NO activity, thereby inhibiting monocyte adhesion to the blood vessel wall and promoting vasodilation. On the other hand, low shear stress is accompanied by reduced NO activity, exaggerated vasoconstriction, and platelet aggregation. Regions of low shear stress are vulnerable to atherosclerosis (typically seen in the arterial branches or bifurcations). Non-aligned cells are found in low shear stress areas whereas aligned cells are found in high shear stress areas. These observations emphasize that endothelial functions are sensitive to hemodynamic changes in the circulatory state.
Summary

The endothelium is an important organ which governs and maintains cardiovascular homeostasis. Located strategically between the blood stream and vascular smooth muscle, it plays a critical role in maintaining cardiovascular health. Normal endothelial function is responsible for physiological blood flow, oxygenation, and prevention of thrombus formation. Endothelial dysfunction predisposes to vasoconstriction, hypoxemia, and thrombus formation leading to ischemia and infarction of the tissue. Endothelial damage has widespread pathophysiological consequences and implications. Abnormal endothelial function promotes vascular inflammation and vascular hypertrophy. The end result of endothelial dysfunction is vascular insufficiency and target organ damage. Risk factors which predispose to endothelial damage include – hypertension, diabetes, hyperlipidemia, tobacco consumption, obesity, sedentary life style, and genetic factors [Figures 7 and 8]. To prevent vascular disease and to protect endothelial function, risk factors should be identified early and treated aggressively. In addition to the control of risk factors, vascular health can be maintained by therapies which promote NO release. Thus, a broad spectrum therapeutic approach is required to maintain endothelial integrity and cardiovascular health. Understanding of endothelial physiology and pathophysiology is necessary to preserve and to protect global public health.

References

1. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
2. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22 Suppl 4:S1-14.
3. Meredith IT, Yeung AC, Weidinger FF, Anderson TJ, Uehata A, Ryan TJ. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993;87 Suppl 5:S56-66.
4. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation 1992;86 Suppl 3:III12-9.
5. Vaughan DE. Thrombotic effects of angiotensin. J Myocard Ischemia 1995;7 Suppl 1:44-9.
6. Radomski MW, Palmer RM, Moncada S. The antiaggregating
properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-46.
7. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995;38:87-104.
8. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;92:3424-30.
9. Muller-Estrl W. Kininogen, kinins and kinships. Thromb Haemostat 1989;61:2-6.
10. Purchott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
11. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide, and prostacyclin on platelets. Br J Pharmacol 1987;92:181-7.
12. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992;262:H611-5.
13. Crossman DC, Larkin SW, Fuller RW, Davies GJ, Maseri A. Substance P dilates epicardial coronary arteries and increases coronary blood flow in humans. Circulation 1989;80:475-84.
14. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990;87:5193-7.
15. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991;88:4651-5.
16. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995;25:155-61.
17. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994;14:653-5.
18. Tsao PS, Lewis NP, Alpert S, Cooke JP. Exposure to shear stress alters endothelial adhesiveness: Role of nitric oxide. Circulation 1995;92:3513-9.
19. Barbee KA, Mundel T, Lal R, Davies PF. Subcellular distribution of shear stress at the surface of flow-aligned and nonaligned endothelial monolayers. Am J Physiol (Heart Circ Physiol) 1995;268:H1765-72.
20. Levesque MJ, Nerem RM. Elongation and orientation of endothelial cell shape in response to shear. J Biomech Eng 1985;107:341-7.

How to cite this article: Wali M, Ram CVS. Endothelial Function and Cardiovascular Health. Hypertens 2021;7(1):7-13.

Source of support: Nil, Conflicts of interest: None